Amendments to the Claims

Without prejudice or disclaimer, this listing of claims will replace all prior versions and listing of claims in this application.

Claim 1 (original). Crystalline 2,5-dione-3-(1-methyl-1H-indol-3-yl)-4-[1-(pyridin-2-ylmethyl)piperidin-4-yl]-1H-indol-3-yl]-1H-pyrrole mono-hydrochloride, a hydrate thereof, or mixtures thereof.

Claim 2 (original). Crystalline 2,5-dione-3-(1-methyl-1H-indol-3-yl)-4-[1-(pyridin-2-ylmethyl)piperidin-4-yl]-1H-indol-3-yl]-1H-pyrrole mono-hydrochloride, a hydrate thereof, or mixtures thereof, having an X-ray diffraction pattern which comprises the following peaks: 6.8 ± 0.1 , 10.9 ± 0.1 , 14.2 ± 0.1 and $16.6 \pm 0.1^{\circ}$ in 20; when the pattern is obtained from a copper radiation source (CuK α ; λ = 1.54056 Å).

Claim 3 (original). The crystalline mono-hydrochloride of claim 2 having an X-ray diffraction pattern which further comprises the following peaks: 6.3 ± 0.1 , 7.2 ± 0.1 , 12.5 ± 0.1 and $17.0 \pm 0.1^{\circ}$ in 2θ .

Claim 4 (presently amended). A pharmaceutical composition comprising a salt of any one of claims 1 3 claim 1 and a pharmaceutical carrier.

Claim 5 (presently amended). A method of treating non-Hodgkins lymphoma which comprises administering to a mammal in need thereof an effective amount of a compound of any one of claims 1-3 claim 1.

Claim 6 (presently amended). A method of treating glioblastoma which comprises administering to a mammal in need thereof an effective amount of a compound of any one of claims 1-3 claim 1.

Claim 7 (presently amended). A method of treating non-small cell lung cancer which comprises administering to a mammal in need thereof an effective amount of a compound of any one of claims 1-3 claim 1.

Claims 8 - 14 (canceled).

Claim 15 (new). A pharmaceutical composition comprising a salt of claim 2_and a pharmaceutical carrier.

Claim 16 (new). A pharmaceutical composition comprising a salt of claim 3_and a pharmaceutical carrier.

Claim 17 (new). A method of treating non-Hodgkins lymphoma which comprises administering to a mammal in need thereof an effective amount of a compound of claim 2.

Claim 18 (new). A method of treating non-Hodgkins lymphoma which comprises administering to a mammal in need thereof an effective amount of a compound of claim 3.

Claim 19 (new). A method of treating glioblastoma which comprises administering to a mammal in need thereof an effective amount of a compound of claim 2.

Claim 20 (new). A method of treating glioblastoma which comprises administering to a mammal in need thereof an effective amount of a compound of claim 3.

Claim 21 (new). A method of treating non-small cell lung cancer which comprises administering to a mammal in need thereof an effective amount of a compound of claim 2.

Claim 22 (new). A method of treating non-small cell lung cancer which comprises administering to a mammal in need thereof an effective amount of a compound of claim 3.